MannKind Corporation (MNKD)
| Market Cap | 861.54M |
| Revenue (ttm) | 348.97M |
| Net Income (ttm) | 5.86M |
| Shares Out | 308.80M |
| EPS (ttm) | 0.02 |
| PE Ratio | 139.50 |
| Forward PE | 390.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,591,270 |
| Open | 2.670 |
| Previous Close | 2.630 |
| Day's Range | 2.650 - 2.810 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 8.69 (+211.47%) |
| Earnings Date | May 8, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price target is $8.69, which is an increase of 211.47% from the latest price.
News
MannKind Transcript: Barclays 28th Annual Global Healthcare Conference
The organization is rapidly transforming into a diversified commercial entity, expecting double-digit revenue growth and two major product launches this year. Key partnerships, product innovation, and international expansion are driving momentum, with a strong financial position supporting future growth.
MannKind Transcript: Leerink Global Healthcare Conference 2026
Management outlined a strategic shift to diversified, high-growth revenue streams, with FUROSCIX® and Afrezza now surpassing royalty income. Major launches and pipeline milestones are expected in 2024. Cost reductions and productivity gains are anticipated from the auto-injector, while the company targets pediatric and hospital market opportunities.
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured a...
MannKind Announces Settlement of Convertible Senior Notes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal am...
MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Revenue grew 46% to nearly $350 million in 2025, with projections above $450 million in 2026 driven by pipeline progress and product launches. Key clinical programs, including MNKD-201 for IPF and Afrezza pediatric expansion, are advancing, while FUROSCIX and Tyvaso DPI royalties support long-term growth.
MannKind Earnings Call Transcript: Q4 2025
Record 2025 revenue of $349M was driven by Afrezza and FUROSCIX growth, with strong Q4 results and a diversified portfolio. Upcoming catalysts include Afrezza pediatric and FUROSCIX auto-injector launches, while Tyvaso DPI royalties and a robust pipeline support future growth.
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to pre...
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MannKind Provides Business Updates and 2026 Growth Drivers
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Shares FUROSCIX® Business Updates
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and conveni...
MannKind Transcript: Jefferies London Healthcare Conference 2025
Significant clinical and commercial progress includes FUROSCIX's rapid sales growth, expanded indications, and a robust pipeline with nintedanib and bumetanide. AFREZZA's pediatric and gestational diabetes trials highlight new market opportunities, while Q3 revenues surpassed $100M.
MannKind to Present at the Jefferies Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Transcript: Study Update
The phase III trial of nebulized clofazimine for NTM lung disease was discontinued due to lack of efficacy, likely related to formulation and dose delivery issues. Focus now shifts to the dry powder formulation, with phase I preparations underway and further data analysis ongoing.
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a ...
MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Di...
MannKind Earnings Call Transcript: Q3 2025
Record Q3 revenue of $82M was driven by TYVASO DPI and Afrezza growth, with FUROSCIX set to boost future sales following the SC Pharmaceuticals acquisition. Pipeline progress and new collaborations support a strong outlook, despite competitive and reimbursement challenges.
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v.
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released befor...
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action ...